AmericasENPublic regulatory overview
Brazil
Market Overview Population: Approximately 215 million (2024), the largest country in Latin America Healthcare system: Dualtrack structure — the public Sistema Único de Saúde (SUS)...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAStrong benefitFDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditStrong benefitMDSAP can reduce duplicate QMS audit burden and may be accepted as a substitute or strong audit evidence.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Brazil
- Product line: Medical devices
- Regulator / source: Regulatory maturity: High — ANVISA (Agência Nacional de Vigilância Sanitária) is the most technically sophisticated regulatory authority in Latin America. The regulatory framework is comprehensive, technical review is rigorous, and reviewers are highly specialized — though administrative efficiency is constrained by limited resources
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Market characteristics: The largest medical device market in Latin America, with annual imports of approximately USD 5 billion. Domestic manufacturing is active, particularly in the cardiovascular and orthopedic segments where local companies are well established. SUS centralized procurement creates intense price pressure; the private channel offers better margin opportunities
- Local requirement: Note: Classification is governed by RDC 752/2022, based on intended use, contact duration, and invasiveness. Importers should confirm classification before proceeding — misclassification is the most common early-stage error.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 215 million (2024), the largest country in Latin America
- Healthcare system: Dual-track structure — the public Sistema Único de Saúde (SUS) covers approximately 75% of the population; private insurance and private hospitals serve middle- and upper-income groups
- Market characteristics: The largest medical device market in Latin America, with annual imports of approximately USD 5 billion. Domestic manufacturing is active, particularly in the cardiovascular and orthopedic segments where local companies are well established. SUS centralized procurement creates intense price pressure; the private channel offers better margin opportunities
- Regulatory maturity: High — ANVISA (Agência Nacional de Vigilância Sanitária) is the most technically sophisticated regulatory authority in Latin America. The regulatory framework is comprehensive, technical review is rigorous, and reviewers are highly specialized — though administrative efficiency is constrained by limited resources
Regulatory Authority
- Primary authority: ANVISA (Agência Nacional de Vigilância Sanitária)
- Official portal: https://www.gov.br/anvisa/pt-br; electronic filing system: SOLICITA (https://solicita.anvisa.gov.br)
- Key regulations:
- RDC 185/2001 (general medical device registration rules, now superseded)
- RDC 751/2022 (medical device registration and notification — replaces RDC 185)
- RDC 752/2022 (medical device classification)
- IN 79/2022 (technical documentation requirements)
- RDC 657/2022 (post-market surveillance)
- Lei 6.360/1976 (health surveillance framework law)
- RDC 36/2015 (healthcare facility vigilance)
Device Classification
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Classe I | Low risk | EU Class I / FDA Class I | Notification pathway (Cadastro); no technical review required |
| Classe II | Low-moderate risk | EU Class IIa / FDA Class II | Registration pathway (Registro); technical review required |
| Classe III | Moderate-high risk | EU Class IIb / FDA Class II-III | Registration pathway; complete technical documentation and clinical evidence required |
| Classe IV | High risk | EU Class III / FDA Class III | Registration pathway; most stringent review; local clinical studies or testing may be required |
Note: Classification is governed by RDC 752/2022, based on intended use, contact duration, and invasiveness. Importers should confirm classification before proceeding — misclassification is the most common early-stage error.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.